KEYMAKER-U01 substudy 01A: Phase 1/2 study of pembrolizumab plus ifinatamab deruxtecan (I-DXd) or patritumab deruxtecan (HER3-DXd) with or without chemotherapy in untreated stage IV non–small-cell lung cancer.

Authors: Charu Aggarwal, Tibor Csőszi, Zsuzsanna Szalai, Jair Bar, Nir Peled, Byoung Chul Cho, Yu Jung Kim, Dariusz M. Kowalski, Ernest Nadal, Jiaxin Niu, Justin F. Gainor, David Paul Carbone, Konstantin H. Dragnev, Kevin Chen, David W. Sternberg, Bin Zhao, Heng Zhou, Azadeh Namakydoust, Vamsidhar Velcheti

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps8652

Source: Full article

---

Abstract

TPS8652